The inseparable relationship between immunity, inflammation, and cancer has been widely reported.[49,50] Previous studies have shown that TLRs are negative regulators of cancer and activation of TLRs can lead to activation of MAPKs and NF-κB.[51] However, it has also been found that some TLRs are found in many tumors and produce the effect of tumor cell proliferation and resistance to chemotherapy, but depend on the TLR and tumor type.[52] The role of the NF-κB pathway in cancer is a double-edged sword. This evidence concerns the gene NFKB1 and neoplasm.